한글목차

미글루스타트의 주요 성장 촉진요인

1. 시장 점유율 확대 및 신규 환자 수 증가

• 미글루스타트는 희귀질환인 리소좀 축적증 시장, 특히 고셔병 1형과 니만픽병 C형(NPC)에서 효소대체요법을 대체할 수 있는 경구용 기질감소요법(SRT)의 중요한 대안으로 강력한 입지를 유지하고 있습니다.
• 진단율 향상, 유전자 스크리닝 개선, 질병에 대한 인식 개선으로 대사 및 신경학 전문센터에서 신규 환자의 치료 시작을 촉진하고 있습니다.
• 의사들의 오랜 친숙함과 확립된 치료 가이드라인이 전 세계에서 지속적인 채택을 지원하고 있습니다.

2. 중요한 적응증으로 확대

• 니만픽병 C형(NPC) : 미글루스타트는 당지질 축적을 감소시켜 신경질환의 진행을 늦추기 위해 널리 사용되고 있습니다.
• 고셔병 1형: 효소대체요법에 적합하지 않은 환자를 위한 경구 대체요법으로 사용됩니다.
• 신경퇴행성 리소좀 질환: 추가적인 리소좀 축적 질환에 대한 적응증 외 사용과 연구에 대한 관심이 높아지면서 임상 연구 확대에 박차를 가하고 있습니다.
• 바이오마커에 기반한 환자 식별: 유전자형과 표현형의 상관관계에 대한 지속적인 연구로 적격 환자 식별 범위가 확대되고 있습니다.

3. 지역적 확장

• 미글루스타트는 희귀질환 보험급여를 통해 유럽, 북미, 아시아태평양, 라틴아메리카에서 시판되고 있습니다.
• 유럽이 가장 큰 시장인 반면, 아시아태평양은 희귀질환에 대한 진단과 접근성이 향상됨에 따라 더 빠른 성장이 기대되는 지역으로 부상하고 있습니다.
• 각 제조업체들은 보급 촉진을 위해 전문 유통망 강화, 병원과의 제휴, 환자 접근 프로그램 확대에 힘쓰고 있습니다.

4. 신규 적응증 승인

• 미글루스타트는 여러 지역에서 NPC와 고셔병 1형에 대한 규제 당국의 승인을 받았습니다.
• 현재 진행 중인 실제 임상 데이터와 업데이트된 가이드라인은 특정 리소좀 축적증 환자를 위한 치료 옵션으로서 경구용 SRT의 효능을 지속적으로 지원하고 있습니다.
• 지속적인 임상 연구를 통해 향후 관련 대사성 질환에 대한 적응증 확대에 도움이 될 수 있습니다.

5. NPC와 고셔병의 강력한 수량 추이

• NPC는 만성적인 신경학적 진행으로 지속적인 장기 치료가 필요하므로 중요한 성장 촉진요인으로 남아있습니다.
• 고셔병 1형은 특히 정맥요법에서 경구요법으로 전환하는 환자에서 안정적인 수치를 보이고 있습니다.
• 리얼월드 레지스트리는 질환의 지속적인 안정화와 기능적 개선을 보여줌으로써 처방의사의 신뢰를 지원하고 있습니다.

6. 경쟁 차별화 및 시장 동향

• 경구용 저분자 기질 감소 요법은 평생에 걸친 정맥내 효소 보충 요법에 대한 편리한 대안을 제공합니다.
• 미글루스타트의 중추신경계 침투성은 많은 효소치료제와 차별화됩니다.
• 정밀 희귀질환 치료, 유전자 스크리닝, 장기적인 질병 치료로 향하는 시장 동향이 지속적인 채택을 지원하고 있습니다.
• 리얼월드에비던스(RWE)에 대한 의존도가 높아짐에 따라 보험사와 임상의의 신뢰성이 강화되고 있습니다.

미글스타트의 최근 발전

2026년 2월, 아미쿠스 테라퓨틱스는 파브리병에 대한 갈라폴드(미갈라스타트)와 지연성 폼페병에 대한 POMBILITI+OPFOLDA(시파글루코시다아제 알파+미글루스타트)에 대한 새로운 임상 및 리얼월드 연구 데이터를 발표했습니다.

세계 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 스페인, 영국, 일본)의 미글스타트(Miglustat) 시장에 대해 조사 분석했으며, 각국 시장 규모와 예측, 연구개발(R&D) 활동, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 리포트의 개요

제2장 미글루스타트 개요 : 고셔병 I형 및 니만픽크병 C형 등의 승인된 적응증, 낭포성 섬유증 및 고셔병 III형 등의 잠재적 적응증

제3장 미글루스타트의 경쟁 상황(출시의 치료법)

제4장 경쟁 구도(후기 단계의 새로운 미글루스타트 요법)

제5장 미글루스타트 시장 평가

제6장 미글루스타트 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving Miglustat Growth

1. Market Share Gains and New Patient Starts

• Miglustat continues to maintain a strong presence in the rare lysosomal storage disorder market, particularly in Gaucher disease type 1 and Niemann-Pick disease type C (NPC), where oral substrate reduction therapy (SRT) is a key alternative to enzyme replacement therapy.
• Increasing diagnosis rates, improved genetic screening, and greater disease awareness are driving new patient starts across metabolic and neurology specialty centers.
• Long-term physician familiarity and established treatment guidelines are supporting sustained global adoption.

2. Expansion Across Key Indications

• Niemann-Pick Disease Type C (NPC): Miglustat is widely used to slow neurological disease progression by reducing glycosphingolipid accumulation.
• Gaucher Disease Type 1: Used as an oral alternative for patients unsuitable for enzyme replacement therapy.
• Neurodegenerative Lysosomal Disorders: Growing off-label and research interest in additional lysosomal storage diseases supports broader clinical exploration.
• Biomarker-Driven Patient Identification: Ongoing work in genotype-phenotype correlations is expanding identification of eligible patients.

3. Geographic Expansion

• Miglustat is marketed across Europe, North America, Asia-Pacific, and Latin America, supported by rare disease reimbursement frameworks.
• Europe remains the largest market, while Asia-Pacific is emerging as a faster-growing region due to improving rare disease diagnostics and access.
• Manufacturers are strengthening specialty distribution, hospital partnerships, and patient access programs to drive uptake.

4. New Indication Approvals

• Miglustat has received regulatory approvals for NPC and Gaucher disease type 1 in multiple regions.
• Ongoing real-world data and guideline updates continue to reinforce oral SRT as a treatment alternative for select lysosomal storage disorder patients.
• Continued clinical research may support future label expansions in related metabolic disorders.

5. Strong NPC and Gaucher Volume Momentum

• NPC remains a major growth driver, with sustained long-term treatment due to chronic neurological progression.
• Gaucher disease type 1 contributes stable volumes, particularly in patients transitioning from infusions to oral therapy.
• Real-world registries demonstrate durable disease stabilization and functional benefits, supporting prescriber confidence.

6. Competitive Differentiation and Market Trends

• Oral small-molecule substrate reduction therapy provides a convenient alternative to lifelong intravenous enzyme replacement.
• Miglustat's central nervous system penetration differentiates it from many enzyme therapies.
• Market trends toward precision rare disease medicine, genetic screening, and long-term disease modification support continued adoption.
• Increasing reliance on real-world evidence (RWE) is strengthening payer and clinician confidence.

Miglustat Recent Developments

In February 2026, Amicus Therapeutics announced the presentation of new data from clinical and real-world studies of Galafold (migalastat) in Fabry disease and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease.

"Miglustat Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Miglustat for approved indication like Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III in the 7MM. A detailed picture of Miglustat's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Miglustat for approved and potential indications. The Miglustat market report provides insights about Miglustat's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Miglustat performance, future market assessments inclusive of the Miglustat market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Miglustat sales forecasts, along with factors driving its market.

Miglustat Drug Summary

Miglustat (Zavesca) is an oral iminosugar and competitive inhibitor of glucosylceramide synthase, the first enzyme in glycosphingolipid biosynthesis, indicated as monotherapy for adult patients with mild to moderate type 1 Gaucher disease who cannot receive enzyme replacement therapy (ERT) due to intolerance, hypersensitivity, or poor venous access (e.g., allergy to imiglucerase), as well as in combination with cipaglucosidase alfa-atga (Pombiliti) for long-term ERT in adults weighing >=40 kg with late-onset Pompe disease who are not adequately improving on their current ERT regimen. By reducing the synthesis of glucosylceramide-based glycosphingolipids to a level manageable by residual glucocerebrosidase activity (substrate reduction therapy), it decreases accumulation in macrophages, improving hepatosplenomegaly, cytopenias (anemia, thrombocytopenia), and bone disease in Gaucher disease type 1, while enhancing lysosomal GAA stabilization/trafficking and clinical outcomes (respiratory/motor function) in Pompe disease. Administered as 100 mg capsules (typically 100-200 mg 1-3 times daily without regard to food for Gaucher; every other week ~1 hour prior to cipaglucosidase for Pompe), miglustat requires monitoring for gastrointestinal effects (diarrhea, nausea), thrombocytopenia, and tremor, with dose adjustments based on tolerability. The report provides Miglustat's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Miglustat Market Report

The report provides insights into:

• A comprehensive product overview including the Miglustat MoA, description, dosage and administration, research and development activities in approved indications like Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III.
• Elaborated details on Miglustat regulatory milestones and other development activities have been provided in Miglustat market report.
• The report also highlights Miglustat's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Miglustat market report also covers the patents information, generic entry and impact on cost cut.
• The Miglustat market report contains current and forecasted Miglustat sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Miglustat market report also features the SWOT analysis with analyst views for Miglustat in approved and potential indications.

Methodology:

The Miglustat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Miglustat Analytical Perspective by DelveInsight

• In-depth Miglustat Market Assessment

This Miglustat sales market forecast report provides a detailed market assessment of Miglustat for approved indication like Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Miglustat sales data uptil 2034.

• Miglustat Clinical Assessment

The Miglustat market report provides the clinical trials information of Miglustat for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Miglustat Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Miglustat Market Potential & Revenue Forecast

• Projected market size for the Miglustat and its key indications
• Estimated Miglustat sales potential (Miglustat peak sales forecasts)
• Miglustat Pricing strategies and reimbursement landscape

Miglustat Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Miglustat Market positioning compared to existing treatments
• Miglustat Strengths & weaknesses relative to competitors

Miglustat Regulatory & Commercial Milestones

• Miglustat Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Miglustat Clinical Differentiation

• Miglustat Efficacy & safety advantages over existing drugs
• Miglustat Unique selling points

Miglustat Market Report Highlights

• In the coming years, the Miglustat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Miglustat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Miglustat's dominance.
• Other emerging products for Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III are expected to give tough market competition to Miglustat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Miglustat in approved and potential indications.
• Analyse Miglustat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Miglustat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Miglustat in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Miglustat? How strong is Miglustat's clinical and commercial performance?
• What is Miglustat's clinical trial status in each individual indications such as Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Miglustat Manufacturers?
• What are the key designations that have been granted to Miglustat for approved and potential indications? How are they going to impact Miglustat's penetration in various geographies?
• What is the current and forecasted Miglustat market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Miglustat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Miglustat for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Miglustat? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Miglustat Overview in approved indications like Gaucher's disease type I and Niemann-Pick disease type C; as well as potential indications like Cystic fibrosis and Gaucher's disease type III

• 2.1. Product Detail
• 2.2. Miglustat Clinical Development
  • 2.2.1. Miglustat Clinical studies
  • 2.2.2. Miglustat Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Miglustat Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Miglustat Therapies)

5. Miglustat Market Assessment

• 5.1. Miglustat Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Miglustat Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Miglustat Market Size in the United States for approved and potential indications
  • 5.3.2. Miglustat Market Size in Germany for approved and potential indications
  • 5.3.3. Miglustat Market Size in France for approved and potential indications
  • 5.3.4. Miglustat Market Size in Italy for approved and potential indications
  • 5.3.5. Miglustat Market Size in Spain for approved and potential indications
  • 5.3.6. Miglustat Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Miglustat Market Size in Japan for approved and potential indications

6. Miglustat SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options